46 results on '"Prieto-Peña D"'
Search Results
2. AB1314 JANUS KINASE INHIBITORS IN REFRACTORY AUTOINFLAMMATORY SYNDROMES. TWO CASE REPORTS AND LITERATURE REVIEW.
3. POS0804 TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY
4. AB0145 IgA VASCULITIS AND IgA NEPHROPATHY SHARE A SIMILAR IL33-IL1RL1 ASSOCIATION PATTERN
5. POS0203 PREDICTIVE SEVERITY FACTORS OF COVID-19 IN PATIENTS WITH RHEUMATIC IMMUNE MEDIATED DISEASES
6. AB0907 TREATMENT WITH UPADACINITIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF FIRST PATIENTS OF CLINICAL PRACTICE
7. AB1431 EPIDEMIOLOGICAL AND GENETIC FEATURES OF ANTI-3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE NECROTIZING MYOPATHY IN NORTHERN SPAIN: SINGLE-CENTER EXPERIENCE
8. AB1341 ASSESSMENT OF COMMON FEMORAL VEIN INTIMA-MEDIA THICKNESS BY ULTRASOUND IN BEHÇET’S DISEASE: COMPARATIVE STUDY OF PATIENTS WITH OR WITHOUT VASCULAR INVOLVEMENT IN A NATIONAL REFERRAL CENTER
9. POS0128 MICROVASCULAR INVOLVEMENT IN BEHÇET’S DISEASE. STUDY OF NAILFOLD CAPILLAROSCOPY AND ENDOTHELIAL PROGENITOR CELLS IN A NATIONAL REFERRAL CENTER
10. AB0679 INTRAVENOUS INMUNOGLOBULIN IN INFLAMMATORY MYOPATHIES: EXPERIENCE OF A SINGLE REFERRAL CENTER
11. POS0405 INCREASED LEVELS OF CELLULAR ADHESION MOLECULES ARE LINKED TO THE PRESENCE OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH AUTOIMMUNE DISEASES
12. POS0052 ANGIOGENIC T CELLS AS RELEVANT PLAYERS IN THE LUNG VASCULOPATHY OF RHEUMATOID ARTHRITIS, SYSTEMIC SCLEROSIS AND OTHER AUTOIMMUNE DISEASES
13. AB1147 COVID 19 INFECTION IN PATIENTS WITH RHEUMATIC IMMUNE-MEDIATED DISEASES IN A SINGLE UNIVERSITY HOSPITAL. MATCHED CASE-CONTROL STUDY.
14. AB0146 BAFF, APRIL y BAFFR: DIFFERENTIAL BIOMARKERS BETWEEN IgA VASCULITIS AND IgA NEPHROPATHY?
15. POS1467-HPR SEVERE RESPIRATORY INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS WITH BIOLOGIC THERAPY. COMPARATIVE STUDY BETWEEN VACCINATED AND NON VACCINATED PATIENTS
16. POS0113 BAFF-APRIL-BAFFR PATHWAY ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS
17. OP0060 COMPARATIVE STUDY ON ANTI-TNF VS TOCILIZUMAB FOR TREATMENT OF REFRACTORY UVEITIC CYSTOID MACULAR EDEMA DUE TO BEHCET’S DISEASE. MULTICENTER STUDY OF 49 PATIENTS
18. AB0365 CLINICAL, LABORATORY AND IMAGING OUTCOMES IN TOCILIZUMAB-TREATED PATIENTS WITH LARGE VESSEL-GIANT CELL ARTERITIS ACCORDING TO EARLY ONSET THERAPY
19. AB0688 SEVERITY OF COVID-19 INFECTION IN RHEUMATIC IMMUNE-MEDIATEDINFLAMMATORY DISEASES. STUDY IN A SINGLE UNIVERSITY HOSPITAL
20. POS1346 CLINICAL ASSOCIATIONS OF ANTI-RO52 ANTIBODIES IN PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES
21. AB0366 TOCILIZUMAB FOR TAKAYASU ARTERITIS: MULTICENTER STUDY OF 54 WHITE PATIENTS
22. AB0430 CONTRIBUTION OF SCLERODERMA/MYOSITIS-RELATED ANTIBODIES DETECTED BY IMMUNOBLOT TO THE DIAGNOSIS OF SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES IN 134 PATIENTS FROM A SINGLE REFERRAL CENTER
23. AB0096 IGA VASCULITIS AND IGA NEPHROPATHY SHARE A SIMILAR IL17A ASSOCIATION PATTERN
24. POS1231 COVID-19 INFECTION IN RHEUMATIC IMMUNE-MEDIATED INFLAMMATORY DISEASES. EPIDEMIOLOGICAL STUDY IN A SINGLE UNIVERSITY HOSPITAL
25. POS0337 SOUTHEND PRE-TEST PROBABILITY SCORE AND HALO SCORE AS MARKERS FOR DIAGNOSIS AND MONITORING OF GCA: EARLY RESULTS FROM THE PROSPECTIVE HAS-GCA STUDY
26. AB0094 INCREASE OF ENDOTHELIAL PROGENITOR CELLS IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
27. AB0026 DECREASE OF ANGIOGENIC T CELLS IN CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE
28. OP0033 OPTIMIZATION OF TOCILIZUMAB THERAPY IN GIANT CELL ARTERITIS. A MULTICENTER REAL-LIFE STUDY OF 134 PATIENTS
29. THU0297 SERIOUS INFECTIONS IN 134 PATIENTS WITH GIANT CELL ARTERITIS WITH TOCILIZUMAB IN CLINICAL PRACTICE. FREQUENCY, TYPE AND CLINICAL ASSOCIATIONS
30. AB1055 CERTOLIZUMAB PEGOL: A SAFE AND EFFICIENT TREATMENT IN PATIENTS WITH UVEITIS DURING PREGNANCY.
31. SAT0270 TOCILIZUMAB IN REFRACTORY TAKAYASU ARTERITIS. OPEN-LABEL NATIONAL MULTICENTER STUDY OF 53 PATIENTS OF CLINICAL PRACTICE
32. SAT0568 PERSISTENT VASCULAR 18F-FDG UPTAKE DESPITE CLINICAL-ANALYTICAL REMISSION IN PATIENTS WITH LARGE VESSEL VASCULITIS UNDER TOCILIZUMAB THERAPY. SINGLE UNIVERSITARY CENTER EXPERIENCE OF 30 PATIENTS.
33. AB0011 INFLUENCE OF IL17A GENE ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS
34. FRI0504 TOCILIZUMAB IN GRAVES’ ORBITOPATHY. MULTICENTER STUDY OF 48 PATIENTS.
35. AB0012 ROLE OF IRF5 GENE ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS
36. FRI0215 RESPONSE TO TOCILIZUMAB IN LARGE VESSEL VASCULITIS ACCORDING TO THE EXTENT OF BASELINE 18F-FDG VASCULAR UPTAKE
37. AB0242 SURVIVAL ANALYSIS IN THE DEVELOPMENT OF SERIOUS INFECTIONS AND SERIOUS RESPIRATORY INFECTIONS IN AR PATIENTS INCLUDED IN A VACCINATION PROGRAM
38. TREATMENT WITH UPADACINITIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF 101 PATIENTS OF CLINICAL PRACTICE.
39. EPIDEMIOLOGY AND CLINICAL FEATURES OF IDIOPATHIC INFLAMMATORY MYOPATHIES IN SINGLE REGION IN NORTHERN SPAIN.
40. REMISSION IN ANTI-HMGCR POSITIVE IMMUNEMEDIATED NECROTIZING MYOPATHY WITHOUT THE USE OF GLUCOCORTICOIDS: A MULTICENTRIC STUDY OF 24 PATIENTS.
41. ANTI-HMGCR AUTOANTIBODY LEVELS IN THE FOLLOW-UP OF STATIN-INDUCED IMMUNE-MEDIATED NECROTIZING MYOPATHY. MULTICENTRIC STUDY OF 24 PATIENTS.
42. ANCA-ASSOCIATED VASCULITIS (AAV) AND RENAL DISEASE IN A MULTIDISCIPLINARY OUTPATIENT CLINIC IN NORTHERN SPAIN.
43. EFFECTIVENESS OF JANUS KINASE INHIBITORS IN GIANT CELL ARTERITIS IN CLINICAL PRACTICE. REAL-WORLD CLINICAL PRACTICE STUDY AND LITERATURE REVIEW.
44. AGE AND SEX BIAS OF ULTRASOUND SCORES FOR DIAGNOSIS OF GIANT CELL ARTERITIS: INSIGHTS FROM THE PROSPECTIVE, LONGITUDINAL HAS-GCA STUDY.
45. PROGNOSTIC FACTORS AND EFFICACY OF DMARD USE IN GCA: RESULTS FROM THE PROSPECTIVE, LONGITUDINAL, MULTI-CENTRE HAS-GCA STUDY.
46. SOUTHEND GCA PROBABILITY SCORE (GCAPS) AND ULTRASOUND HALO SCORE (HS) AS MARKERS FOR DIAGNOSIS AND MONITORING OF GCA: RESULTS FROM THE PROSPECTIVE, MULTICENTER HAS-GCA STUDY.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.